JP7352473B2 - がん細胞を標的化するキメラ抗原受容体のための方法および組成物 - Google Patents

がん細胞を標的化するキメラ抗原受容体のための方法および組成物 Download PDF

Info

Publication number
JP7352473B2
JP7352473B2 JP2019571213A JP2019571213A JP7352473B2 JP 7352473 B2 JP7352473 B2 JP 7352473B2 JP 2019571213 A JP2019571213 A JP 2019571213A JP 2019571213 A JP2019571213 A JP 2019571213A JP 7352473 B2 JP7352473 B2 JP 7352473B2
Authority
JP
Japan
Prior art keywords
cells
car
cell
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528744A (ja
JP2020528744A5 (enExample
Inventor
ジャンピエトロ ドッティ，
ソルダーノ フェローン，
ホンウェイ ドゥ，
シンフイ ワン，
クリスティーナ フェローン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2020528744A publication Critical patent/JP2020528744A/ja
Publication of JP2020528744A5 publication Critical patent/JP2020528744A5/ja
Application granted granted Critical
Publication of JP7352473B2 publication Critical patent/JP7352473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2019571213A 2017-06-21 2018-06-19 がん細胞を標的化するキメラ抗原受容体のための方法および組成物 Active JP7352473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523105P 2017-06-21 2017-06-21
US62/523,105 2017-06-21
PCT/US2018/038289 WO2018236870A2 (en) 2017-06-21 2018-06-19 METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR

Publications (3)

Publication Number Publication Date
JP2020528744A JP2020528744A (ja) 2020-10-01
JP2020528744A5 JP2020528744A5 (enExample) 2021-07-29
JP7352473B2 true JP7352473B2 (ja) 2023-09-28

Family

ID=64691428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571213A Active JP7352473B2 (ja) 2017-06-21 2018-06-19 がん細胞を標的化するキメラ抗原受容体のための方法および組成物

Country Status (10)

Country Link
US (3) US10233226B2 (enExample)
EP (2) EP3642344B1 (enExample)
JP (1) JP7352473B2 (enExample)
CN (1) CN111386347B (enExample)
AU (2) AU2018289428B2 (enExample)
CA (1) CA3068256A1 (enExample)
DK (1) DK3642344T3 (enExample)
ES (1) ES3014942T3 (enExample)
FI (1) FI3642344T3 (enExample)
WO (1) WO2018236870A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068256A1 (en) * 2017-06-21 2018-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
LT3920939T (lt) * 2019-02-08 2025-01-10 Biontech Cell & Gene Therapies Gmbh Ląstelės su modifikuotu chimeriniu antigeno receptoriumi, skirtos cldn6 ekspresuojančio vėžio gydymui
CN109880804B (zh) * 2019-03-06 2022-07-15 徐州医科大学 一种靶向b7h3的car-t细胞的制备方法及应用
CN109929039A (zh) * 2019-03-28 2019-06-25 郑州大学第一附属医院 基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用
CN112390892B (zh) * 2019-08-14 2024-01-12 博源润生医药（杭州）有限公司 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
AU2020387401A1 (en) * 2019-11-18 2022-05-26 Board Of Regents, The University Of Texas System Anti-B7-H3 monoclonal antibody and methods of use thereof
MX2022010176A (es) * 2020-02-20 2023-01-16 Win Therapeutics Inc Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.
US20230174653A1 (en) * 2020-04-06 2023-06-08 St. Jude Children's Research Hospital, Inc. B7-h3 chimeric antigen receptors
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
KR20230098637A (ko) * 2020-11-04 2023-07-04 페이트 세러퓨틱스, 인코포레이티드 이종성 종양 제어를 위한 조작된 iPSC 및 면역 효과기 세포
CN112521512B (zh) * 2020-12-14 2021-09-17 广州百暨基因科技有限公司 抗b7h3嵌合抗原受体及其应用
CN114763381B (zh) * 2021-01-13 2025-01-28 博生吉医药科技(苏州)有限公司 B7-h3嵌合抗原受体修饰的t细胞及其应用
US20240408135A1 (en) * 2021-05-11 2024-12-12 The General Hospital Corporation Methods for treating graft versus host disease
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
WO2024112880A1 (en) * 2022-11-23 2024-05-30 The University Of North Carolina At Chapel Hill B7-h3 targeting ligands and methods of use
CN116699136B (zh) * 2023-06-25 2026-03-17 郑州大学 一种用于胰腺导管腺癌早期筛查和诊断的血清蛋白标志物、应用和相应分析方法
CN117025541B (zh) * 2023-08-15 2025-10-17 福建医科大学附属协和医院 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160053017A1 (en) 2013-03-25 2016-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
IN2014DN08236A (enExample) * 2012-03-03 2015-05-15 Immungene Inc
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
US10174095B2 (en) * 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
CA2982984C (en) * 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2017044699A1 (en) * 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors
CA3068256A1 (en) * 2017-06-21 2018-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160053017A1 (en) 2013-03-25 2016-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gynecologic Oncology，2013年11月09日，Vol. 132，pp. 203-210
Human Melanoma Associated Antigens Identified with Monoclonal Antibodies: Characterization and Potential Clinical Application，Cutaneous Melanoma and Precursor Lesions (Developments in Oncology, Vol.25)，1984年，pp. 19-37

Also Published As

Publication number Publication date
US20180371053A1 (en) 2018-12-27
WO2018236870A2 (en) 2018-12-27
EP3642344A4 (en) 2021-03-31
EP3642344B1 (en) 2024-12-04
CN111386347A (zh) 2020-07-07
AU2018289428A1 (en) 2020-02-06
EP4548927A2 (en) 2025-05-07
FI3642344T3 (fi) 2025-03-13
CA3068256A1 (en) 2018-12-27
JP2020528744A (ja) 2020-10-01
CN111386347B (zh) 2024-08-13
US20200369743A1 (en) 2020-11-26
EP4548927A3 (en) 2025-07-23
ES3014942T3 (en) 2025-04-28
US20190153063A1 (en) 2019-05-23
EP3642344A2 (en) 2020-04-29
WO2018236870A3 (en) 2019-02-07
DK3642344T3 (da) 2025-03-03
AU2018289428B2 (en) 2024-06-27
US10519214B2 (en) 2019-12-31
AU2024220000A1 (en) 2024-10-17
US10233226B2 (en) 2019-03-19

Similar Documents

Publication Publication Date Title
JP7352473B2 (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
JP7451627B2 (ja) キメラ受容体及びその使用方法
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
KR20190021203A (ko) Flt3에 대한 키메라 수용체 및 이의 사용 방법
US11993659B2 (en) BCMA targetting antibodies, chimeric antigen receptors, and uses thereof
CN112771080B (zh) 针对steap1的嵌合受体及其使用方法
JP2019511224A (ja) 抗体及び関連分子並びにその使用
US20250163178A1 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
JP7674243B2 (ja) Ｃａｒを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用
WO2023019398A1 (en) Bcma targetting antibodies, chimeric antigen receptors, and uses thereof
CN115322257B (zh) Bcma靶向抗体、嵌合抗原受体及其应用
WO2017015374A1 (en) Methods and compositions for chimeric antigen receptor targeting the glucose-regulated protein of 94 kda (grp94)
HK40126444A (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
US20230295564A1 (en) Galectin-9 Specific Binding Agents for Use in Treating Cancer
IL310715A (en) Anti-her2 car nk cells, methods of their production and uses thereof
HK40061606B (zh) 嵌合抗原和t细胞受体及使用的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230915

R150 Certificate of patent or registration of utility model

Ref document number: 7352473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150